Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.53 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.51 |
| ▸ | ELANE | P08246 | 4/20 | 0.49 |
| ▸ | CTSG | P08311 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | FFAR1 | O14842 | 5/20 | 0.48 |
| ▸ | PPARD | Q03181 | 5/20 | 0.48 |
| ▸ | PPARG | P37231 | 3/20 | 0.48 |
| ▸ | PPARA | Q07869 | 3/20 | 0.48 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.46 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.46 |
| ▸ | F2 | P00734 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28491464 | 1.00 | HDAC8 (0.53) | HDAC8PTPN1ELANECTSGPOLB | |
| SCHEMBL21957648 | 0.91 | HDAC8 (0.54) | HDAC8SMN1; SMN2PPARG | |
| SCHEMBL31562473 | 0.89 | HDAC8 (0.50) | HDAC8POLBSMN1; SMN2LMNA | |
| SCHEMBL31562314 | 0.89 | L3MBTL1 (0.51) | HDAC8PTPN1ELANESMN1; SMN2FFAR1 | |
| SCHEMBL31562872 | 0.87 | ABCB1 (0.49) | HDAC8PTPN1POLBSMN1; SMN2LMNA | |
| SCHEMBL28491465 | 0.87 | ABCB1 (0.49) | HDAC8PTPN1POLBSMN1; SMN2LMNA | |
| SCHEMBL15348526 | 0.85 | ERN1 (0.63) | HDAC8PTPN1SMN1; SMN2LMNA | |
| SCHEMBL31562597 | 0.85 | PPARD (0.52) | HDAC8POLBSMN1; SMN2FFAR1PPARD | |
| SCHEMBL5556434 | 0.85 | LMNA (0.57) | HDAC8POLBSMN1; SMN2PPARDPPARG | |
| SCHEMBL31562742 | 0.84 | PTGDR2 (0.58) | PTPN1ELANEPOLBSMN1; SMN2PTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250289789-A1 | REVERSIBLE LYSINE COVALENT MODIFIERS OF CDK2 AND USES THEREOF | TERREMOTO BIOSCIENCES, INC. | 2025-09-18 | — | — | US | disclosed |
| WO-2025090658-A2 | REVERSIBLE LYSINE COVALENT MODIFIERS OF CDK2 AND USES THEREOF | TERREMOTO BIOSCIENCES, INC. (US) | 2025-05-01 | — | — | WO | disclosed |
| CN-112074521-B | Compounds as protease activated receptor 4(PAR4) inhibitors for the treatment of platelet aggregation | 深圳信立泰药业股份有限公司 | 2022-08-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250289789-A1 | REVERSIBLE LYSINE COVALENT MODIFIERS OF CDK2 AND USES THEREOF | CDK2, CDK20, CDK1 | HDAC8 117/4885PTPN1 4190/4885ELANE 3834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.